Vascular reactivity in patients with heart failure
Recruiting
- Conditions
- Heart failure
- Registration Number
- NL-OMON22119
- Lead Sponsor
- eiden University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Group 1:
- Diagnosed with heart failure in line with the European Society of Cardiology (ESC) guidelines (McMurray et al., 2012);
Exclusion Criteria
- Age <18 years;
- Incapacitated adults;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Change in SVR after phenylephrine administration
- Secondary Outcome Measures
Name Time Method In vivo<br /><br>- Change in mean arterial pressure (MAP) after phenylephrine administration.<br /><br>- Change in MAP, SVR and CI after nitroglycerin administration.<br /><br>- Vasoplegia<br /><br>- Copeptin, norepinephrine, epinephrine, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), N-terminal prohormone of BNP (NTproBNP), angiotensin II, cortisol, aldosterone, renin and vanillylmandelic acid (VMA) levels<br><br /><br>Ex vivo<br /><br>- Change in vessel diameter in response to vasoactive drugs.<br /><br>- Activated signalling proteins which are associated with vasoresponsiveness.<br /><br>- Receptors (quantity and function) which are associated with vasoresponsiveness.